- Home
- VOR
as 02-21-2025 4:00pm EST
Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VOR33.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 161.9M | IPO Year: | 2021 |
| Target Price: | $11.36 | AVG Volume (30 days): | 415.9K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.65 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.63 - $2.43 | Next Earning Date: | 03-19-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Vor Biopharma Inc. (VOR)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Attar Eyal C. | VOR | CHIEF MEDICAL OFFICER | Feb 10 '25 | Sell | $1.37 | 2,554 | $3,498.98 | 128,852 | |
| Attar Eyal C. | VOR | CHIEF MEDICAL OFFICER | Dec 27 '24 | Sell | $1.25 | 10,334 | $12,917.50 | 128,852 |
Latest Vor Biopharma Inc. News
VOR Breaking Stock News: Dive into VOR Ticker-Specific Updates for Smart Investing
GlobeNewswire
9 days ago
Vor Bio Presents Novel Research Highlighting Opportunities and Challenges Facing Institutions Enrolling Patients in Cell and Gene Therapy Trials
GlobeNewswire
19 days ago
Vor Bio to Participate in the Oppenheimer's 35th Annual Healthcare Life Sciences Conference
Zacks
a month ago
Vor Biopharma Inc. (VOR)'s Technical Outlook is Bright After Key Golden Cross
MT Newswires
a month ago
Vor Biopharma Files Secondary Common Stock Shelf
GlobeNewswire
a month ago
Vor Bio Appoints Life Sciences and Technology Investor and Entrepreneur, Mr. Erez Kalir to its Board of Directors
MT Newswires
2 months ago
JMP Securities Adjusts Price Target on Vor Biopharma to $6 From $12, Keeps Market Outperform Rating
TipRanks
2 months ago
Vor Biopharma Secures $55.6M for Cancer Therapy Trials
GuruFocus.com
2 months ago
Vor Bio Secures $55.6 Million in PIPE Financing, Shares Surge Nearly 47%
Compare VOR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "VOR Vor Biopharma Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.